Wang Hoqing
Henlius Biotech’s heavily invested PD1 blockbuster Hansizhuang (Serpullimab) has been available for the treatment of high microsatellite instability (MSI-H) since it was launched in China in March 2022. It brought about RMB 80 million ($11.6 million) to the company in a month.
Such strong achievements have increased confidence in biotechnology and brought Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) rival, as well as several other assets…
This article is accessible to registered users. Sign up for free to read more. A free trial gives him one week access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space. If you have already registered as a user, please log in. If your trial has expired, you can subscribe here.
Try before you buy
• All the news that makes a difference in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science reporters.
• Receive free daily breaking news from The Pharma Letter forever.
become a subscriber
• Unrestricted access to industry-leading news, commentary and analysis in pharma and biotech.
• Latest information from clinical trials, conferences, M&A, licensing, funding, regulation, patents and law, board appointments, commercial strategy and financial results.
• A daily roundup of important events in pharma and biotechnology.
• Monthly in-depth briefings on board appointments and M&A news.
• Choose from cost-effective annual packages or flexible monthly subscriptions.
